Momenta (MNTA) Shares Edge Higher as UBS Issues Intraday Upgrade
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Momenta Pharmaceuticals (NASDAQ: MNTA) have pushed over the $11 level in mid-day trade as UBS just upgraded the stock from Neutral to Buy in an intraday research note. The firm slightly reduced its price target from $17 to $16.
Momenta shares are currently up about 5 percent to around $11.15. The move higher follows a more than 40 percent decline in the stock over the last three trading sessions as Amphastar received FDA approval for its generic version of Lovenox.
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Momenta shares are currently up about 5 percent to around $11.15. The move higher follows a more than 40 percent decline in the stock over the last three trading sessions as Amphastar received FDA approval for its generic version of Lovenox.
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Create E-mail Alert Related Categories
UpgradesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
